The effect of Uro-vaxom therapy after surgical removal of infected urolithiasis

The effect of Uro-vaxom therapy on urinary citrate lyase activity, urease activity and uro-biome in patients with recently surgical treatment for infected urolithiasis

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CRIS

Registry ID

KCT0007078

Enrollment

Registered

2022-03-11

Start date

2022-07-04

Completion date

Unknown

Last updated

2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : Urovaxom® Main component: standardized lyophyllized of bacterial lysate Dosage: 1 capsule, once daily in the morning Duration: 5~6 months Adm. Route: Orally

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Aged over 20 years 2. Pyuria (WBC > 4 / HPF) with known urolithiasis 3. Asian

Exclusion criteria

Exclusion criteria: 1. Patients who do not want to be enrolled 2. Patients who have urostomy or neobladder 3. Known Gout 4. Known hyperparathyroidism 5. Ongoing chemotherapy due to cancer treatment 6. Drug induced Immunocompromized patients (eg. Lupus, post-transplantation) 7. Pregnancy 8. 2 weeks before or 2 weeks after Live vaccination 9. Allergic reaction to Urovaxom®

Design outcomes

Primary

Measure	Time frame
Urinary E. coli (qPCR method)	—

Secondary

Measure	Time frame
Urinary citrate lyase activity (ELISA method);Urinary urease activity (ELISA method)	—

Countries

Korea, Republic of

Contacts

Public ContactDong-sup Lee

The Catholic University of Korea

bbangbbangi@naver.com+82-31-881-8920

Outcome results